Moderna, Inc.
Analysis
Moderna has kept itself funded through the COVID decline with cost cuts, but everything meant to replace that lost revenue — flu, the COVID-flu shot and its cancer therapy — is still ahead of it. How much of Moderna's 2026 growth is already contracted?
- Growth has moved abroad, and government contracts are doing the work.
U.S. revenue fell from $782 million in Q3 FY2025 to $70 million in Q2 FY2026, while the U.K. partnership carried the first quarter. Management expects an even U.S.-international split, so growth no longer waits on U.S. vaccination rates.
- Cost cuts, not new sales, are what keeps this company running.
Moderna has beaten its own cost plan again, cutting 2025 spending by 30% and lowering the 2026 cash-cost target to about $4 billion. That is what pays for the pipeline while COVID sales shrink, and it still aims to break even in 2028. Which part of Moderna's cost base is idle capacity?
- Two pipeline bets failed, and regulators are still the biggest unknown.
CMV was discontinued, norovirus missed the bar for stopping its trial early, and flu drew a Refusal-to-File. Flu has since won a unanimous advisory vote and an August 5 date, but it still leaves Moderna's future resting with regulators. What did Moderna's FDA Type A meeting conclude?
- New products replace COVIDThe bull case rests on a wave of newly approved products, from a second COVID shot to a flu-COVID combination, replacing revenue the original COVID vaccine is losing.
- Cost cuts ahead of planManagement has taken costs out faster than it promised, which lowers the revenue needed to break even and gives the pipeline more time to produce results.
- Cancer therapy as second legIntismeran would give Moderna a cancer business unrelated to seasonal vaccination, and its five-year melanoma data are what the bull case for that option rests on.
- COVID base keeps shrinkingThe bear case starts with a COVID business that keeps getting smaller as vaccination rates fall, so each new product has to replace a moving target of lost sales.
- Pipeline setbacks push out revenueThe products meant to fill that gap have slipped: the CMV vaccine failed outright, norovirus needs another season, and flu and the combination contribute nothing yet.
- Cash burn ahead of breakevenEven after deep cost cuts the company still spends more than it takes in, and the breakeven commitment is repeated less firmly as the launch dates move.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$1K | Aug 28 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$15K | Aug 26 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Aug 24 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$1K | May 18 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Mar 17 | May 13 |
Congressional trading data provided by QuiverQuant
How Moderna turned $1.9B of revenue into $1.1B of gross profit.
| Revenue | ||
|---|---|---|
| COVID | $1.8B | |
| Stand-ready manufacturing revenue | $80.0M | |
| Grant revenue | $22.0M | |
| Collaboration revenue | $13.0M | |
| Licensing and royalty revenue | $11.0M | |
| RSV | $8.0M | |
| Total revenue | $1.9B | |
| Gross profit | $1.1B | 55.3% |